Global Renal Denervation Devices Market - 2022-2029

Global Renal Denervation Devices Market - 2022-2029

Market Overview

Renal Denervation Devices Market size was valued US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 36.89% during the forecast period (2022-2029).

Renal denervation (RDN) is a minimally invasive treatment for persistent hypertension or resistant hypertension. Resistant hypertension is essential that does not respond to standard treatment regimens and is a crucial therapeutic challenge. The method uses radiofrequency ablation to burn the nerves in the renal arteries resulting in a reduction in nerve activity. This process causes a decrease in sympathetic kidney activity, which decreases blood pressure. Recent procedures employ catheter-based denervation, where the catheter is introduced through the femoral artery, which is threaded into the renal artery lumen under fluoroscopic control, which is either performed using radiofrequency energy or ultrasound energy.

Market Dynamics

Rising uncontrolled and drug-resistant hypertension cases are expected to fuel the demand for renal denervation.

Advancements in technologies and new therapy systems are expected to drive market growth.

Renal denervation therapies offer numerous advantages, such as permanent effects, high safety, and reduced time for treatment. In May 2019, at the EuroPCR Annual Meeting, held in Paris, Medtronic released the positive trial results of the Symplicity renal denervation system, associated with a reduced occurrence of subclinical atrial fibrillation (AF) in a small portion of high-risk patients with hypertensive heart disease. Moreover, in 2020, the FDA granted breakthrough therapy designation to 2 renal artery denervation systems, SoniVie's Therapeutic Intra-Vascular Ultrasound (TIVUS) System and Recor's Paradise Denervation System, for the treatment of patients with persistently elevated blood pressure. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

However, there are stringent regulatory guidelines for product approval in specific countries, the absence of favorable reimbursement policies and lack of awareness regarding the efficiency and availability of renal denervation therapies are factors expected to hamper the market growth.

Industry Analysis

The renal denervation devices market provides in-depth analysis of the market based on various industry factors such as unmet needs, pricing analysis, supply chain analysis, regulatory analysis etc.

Segment Analysis/B>

Simplicity Renal Denervation System segment is expected to hold the largest market share in the renal denervation devices market.

The simplicity renal denervation system segment accounted for the largest market share in 2021. Simplicity is the renal denervation market's principal and most frequently used product. Since it delivers a low level of RF energy and thus reduces the potential risks associated with high levels of RF radiation on body tissues, this product is preferred over the rest. In addition to this, the device provides a minimally invasive method to treat excessive hypertension. For instance, Medtronic Symplicity Spyral renal denervation system complements medication and lifestyle changes with an effective, evidence-based procedural approach to hypertension treatment. Thus, from the above statements, the market segment accounted for the largest market share in the forecast period.

Geographical Analysis

Europe region is expected to hold the largest market share in the global renal denervation devices market.

Europe accounted for the highest revenue share in 2021. Increasing R&D activities for designing efficient devices, increasing drug-resistant hypertension cases, and product launches and approvals in the area will boost the market over the projection period. For instance, ReCor Medical Inc. launched the ultrasonic renal denervation system in Europe in October 2021, which will be used to treat uncontrolled hypertension in Germany. Moreover, Medtronic PLC reported the first clinical data from the SPYRAL HTN-OFF MED Pivotal Trial in March 2020. The pivotal SPYRAL HTN-OFF MED Pivotal Trial demonstrates that renal denervation is superior to sham surgery in patients with high blood pressure. Therefore, it has increased the demand for renal denervation devices. Thus, from the above statements, the European region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the renal denervation devices market are Medtronic PLC, Cardiosonic, Inc, Kona Medical, Inc, Abbott Laboratories, Ablative Solutions, Inc, Renal Dynamics, Mercator MedSystems, Inc, ReCor Medical, Inc, Boston Scientific Corp, and Terumo Corporation among others.

Medtronic plc:

Overview:

Medtronic plc is an American-Irish registered medical device company primarily operating in the United States. It has an operational and executive headquarters in Fridley, Minnesota, in the US. Moreover, it develops and manufactures devices and therapies to treat more than 30 chronic diseases, including heart failure, Parkinson's disease, urinary incontinence, Down syndrome, obesity, chronic pain, spinal disorders and diabetes. It is operated in 140 countries and employs over 104,950 people.

Product Portfolio:

Symplicity Spyral renal denervation system: The Symplicity Spyral renal denervation system complements medication and lifestyle changes with an effective, evidence-based procedural approach to hypertension treatment.

The global renal denervation devices market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.